The concept of Quality by Design (QbD) as published in ICH-Q8 is currently one of the most recurrent topics in the pharmaceutical literature. This guideline recommends the use of information and prior knowledge gathered during pharmaceutical development studies to provide a scientific rationale for the manufacturing process of a product and provide guarantee of future quality. This poses several challenges from a statistical standpoint and requires a shift in paradigm from traditional statistical practices. First, to provide "assurance of quality" of future lots implies the need to make predictions regarding quality given past evidence and data. Second, the Quality Attributes described in the Q8 guidelines are not always a set of unique, independent measurements. In many cases, these criteria are complicated longitudinal data with successive acceptance criteria over a defined period of time. A common example is a dissolution profile for a modified or extended release solid dosage form that must fall within acceptance limits at several time points. A Bayesian approach for longitudinal data obtained in various conditions of a Design of Experiment is provided to elegantly address the ICH-Q8 recommendation to provide assurance of quality and derive a scientifically sound Design Space.
Introduction
The concept of Quality by Design (QbD) is a regular topic in current pharmaceutical literature. It is most often applied to drug discovery, method development and production. However, this concept is not new. Roots go back as far as the 1950s, when Juran [10] and Deming [3] introduced the concept within the tenets of quality management. More recently, Design For Six Sigma was introduced as a complementary method to the improvement methods of Lean Six Sigma, specifically to use for new product or process development. The fundamental idea is that quality of a product begins, and is sustained, through rigorous product design. If each production process is designed to deliver robust quality, most problems related to the manufacturing of the product could be avoided. Business efficiency resulting from these design methods has led to an expansion of the QbD concept in the pharmaceutical industry.
More recently, the Food and Drug Administration (FDA) and the International Conference for Harmonization (ICH) have seen the opportunity to apply QbD to gain knowledge and understanding about the products and processes of the pharmaceutical industry (see the following regulatory document and guidelines: Food and Drugs Administration, 2007 Administration, , 2011 [20, 21] [9, 7, 8] .
These guidelines rely on the use of information and knowledge gathered during development studies, to provide a scientific rationale for the design of the manufacturing process for a pharmaceutical product (Yu, 2008) [25] . In these guidelines, the Design Space (DS) has been defined as the "the multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality" for the analytical outputs or processes involved in Pharmaceutical Development. This document is clearly devoted to optimization strategies and robustness studies for various processes having Quality Attributes (QA) assessed by various analytical procedures.
QbD emphasizes the elements of product, process understanding, and process control.
It advocates a systematic approach for the development of these elements based on clear and predefined objectives (e.g. the Quality Target Product Profile (QTPP)).
Particularly, the risk that a product or a process will not fulfill the quality requirements must be assessed. Regulatory actions now incorporate this risk-based approach. Hence, pharmaceutical manufacturers must fully comply with these guidelines to be in order to prove their ability to provide high quality medicines. See for instance the recent manual of policies and procedures (MaPP) published by the Food and Drug Administration (2011) [22] . Of course, the interest of the industries is high and goes beyond simply meeting evolving regulatory expectations, as QbD will result in improved quality control (QC). Indeed, as quality is proven during each production step, the final product quality requirements will be more likely met, although final product (release) specifications will still be mandatory. With better understanding and more reliable processes, both variability and rejection rates will be reduced which is a noticeable gain for both the consumers and the producers, in line with risk management expectations (ICH Q9, 2005) [7] .
While conceptually meaningful and relevant to ensure future quality of products, the QbD recommendations pose several challenges from a statistical standpoint, and require a shift in paradigm from traditional statistical practices. First, the concept of providing "assurance of quality" for future lots implies the need to make predictions about the future quality given the past evidence and data. This naturally implies the use of Bayesian statistics to properly address this goal. Second, the Q8 guidelines mention Quality Attributes in general terms, as if there were a unique single attribute or a set of independent attributes. In many cases, the Quality Attributes may be more complex, with complicated correlations structures such as longitudinal data that should successively fall within specifications to meet their global quality requirement.
A common example is the dissolution profile of a modified or extended release solid dosage form product that must fall within acceptance limits at several time points.
Evaluating the predictive probability of success of jointly meeting each set of specifications given the assumed underlying model and high dependencies between measurements is a challenge that may prove cumbersome or even impossible using frequentist statistics. Bayesian approach provides elegant and natural answers.
This work will present a practical solution for the implementation of QbD strategy for repeated measure data with multiple testing time points and conditional retesting of additional units, using dissolution profiles as supporting example. The key statistical challenges to overcome to make QbD a reality for such longitudinal data are critical: It can be postulated that a Bayesian approach is the only option to practically achieve such an objective as required by ICH-Q8. The justification and added value of the use of Bayesian statistics for proper QbD implementation has been discussed extensively by several authors such as Peterson et al. [13] [14] [15] [16] [17] , Miró-Quesada [12] and Lebrun et al. [11] .
An example with Longitudinal Quality Attribute

The dissolution test.
For various dosage forms of products, in vitro dissolution tests or profiles are required for release. In particular, a dissolution profile rather than a single dissolution result is reported to assess the ability of the dosage form to deliver the active pharmaceutical Table 1 .
These limits are product-dependent and defended by the company during the submission process. Since all individual measurements must fall within the limits, it is critical to be able to predict future individual results, instead of a (conditional) mean as is usually done in a frequentist approach. This is further justification for the choice of a Bayesian approach.
<insert Table 1 here> Table 1 : USP <711> three stages acceptance for dissolution testing applied to extended release formulation.
The design of experiments and the design space.
In this example, two critical factors were identified and chosen, based on a risk assessment using historical process data, to analyze their impact on the dissolution profiles. They are named X1 and X2 for simplicity. A designed experiment was conducted to model the impact of X1 and X2, varying both factors across a range centered on the current nominal target settings. Specifically, eight commercial scale batches of the tablets, covering a range of X1 and X2 were used, creating a designed experiment over the X1 and X2 ranges. N=12 tablets were tested at each dissolution interval for each batch, except at the central condition where 24 tablets were analyzed.
The results of one experiment over the 8 over the experimental space, the acceptance time points, and the individual unit dissolution results at each testing time point are represented in Figure 1 (simulated data). The complete experimental domain can be seen on Figure 2 . It was observed that all six results from the first stage of testing fall within the limits at the center of the experimental space (X1=28 and X2=3.9). As conditions move away from the center into the corners of the design, results partially fall outside the acceptance criteria. The central objective in the experiment was to identify the X1 and X2 set of conditions that result in a high probability that the dissolution profile will pass for most future batches, i.e. to estimate a Design Space (DS) for this processing step. <Figure 1 here> [11] proposed an alternative Bayesian multivariate linear model with informative priors by extending the non-informative models proposed by Box and Tiao [1] . When using conjugate prior distributions -informative or not -Lebrun et al. [11] have shown that the (joint) predictive distribution of the responses follows a (multivariate) non-central Student's distribution. Another important result is that the predictive distributions, using either noninformative or informative priors, are of β-expectation (Guttman, 1970) [4] . This means that the highest probability density (HPD) intervals derived from the predictive distribution are the β-expectation joint tolerance intervals (Hamada et al., 2004) [5].
Bayesian Hierarchical longitudinal model
For longitudinal Critical Quality Attributes such as dissolution profiles for extended or modified release dosage forms, a hierarchical (or mixed effect) response surface (RS) linear model (Chib and Carlin, 1999) [2] must be envisaged. When hierarchy is envisaged on one or several parameters of a linear model (i.e. in the presence of random effects), there is generally no closed form available for the predictive distribution of the responses, as the one described in Lebrun et al. [11] . MarkovChain Monte-Carlo methods (MCMC) must therefore be used to sample from the posterior predictive distribution.
For the DoE described above and the dissolution test data shown in Figure 1 , the following mixed-effect model was developed and applied:
! ~Normal(0, ! ), and (Equation 1)
] is structured to account for the variability of the tablets in the vessels and X2 levels.
Because the percentage of API dissolved is a value bounded between 0 and 1, a logit transformation was applied in order to assume a normal distribution for this response. 
Design Space Definition
Assume a process with k process parameters (PP) 
where is a vector of responses that is likely to fall within an acceptance region (A) with a minimal probability or "quality level" π. Acceptance limits are usually previously defined or imposed by regulations before experiments and data analysis are performed. They reflect the quality to be achieved and maintained. The DS is then the set of combinations of input conditions (here, X1 and X2) where the joint posterior probability that future responses lie within acceptance limits is sufficiently high. The 
Results
Bayesian Hierarchical longitudinal model
The model described in Section 3.2 was fit to the experimental data using the MCMChregress function of the MCMCpack package freely available for R. R 2.14 has been used to compute the predictive probabilities at the specified dissolution test time points (hours) and the factor levels. Figure 3 illustrates the predictions of a mean future individual dissolution profile in the original scale, with the prediction (β-expectation tolerance) intervals shown in red. In this last graph, the grey areas indicate the acceptance criteria. Confronting the model to the data allows confirming that the model fit well the data. The MCMC methods allow direct estimation of the predictive distribution and therefore the 95% joint prediction interval. It can also be seen in Figure 3 that the prediction interval seems to fall within specifications at this factor setting of X1 and X2. From the predictions, the risk for the profile to fall outside specification appears to be more sensitive to changes in X2 (results not presented).
The question remains how much change in X1 and X2 would be allowed to ensure with a high probability that all future dissolution tests will meet acceptance criteria. <Figure 3 here> Figure 1 (simulated).
Figure 3: Mean predictions (black) and 95% β-expectation tolerance or prediction intervals (red) and limits or specifications (grey shaded area) for the data depicted in
Design space
For any combination of the X1 and X2 factors, the predictive probability of passing 2) For Stage 1, the probability of success was computed as follows:
-Keep only the 6 first profiles out of 24 profiles generated; given in future routine only 6 units will be tested, -For the 1000 sets of 6 profiles, calculate the proportion of sets where the 6 profiles satisfy the specifications jointly. This proportion is the MCMC estimate of the probability of success at Stage 1.
3) For Stage 2 the probability of success was computed as follows: As it can be seen in Figure 4 , in the center of the domain of the second factor (X2), it is possible to obtain the six Stage 1 profiles within specifications with a high level of confidence, across the full range of X1. The lighter blue area corresponds to a confidence level of about 0.95. The X2 is very critical: at low and high levels of X2, the probability quickly drops to near 0% chance of success at any X1 level. A small interaction between X2 and X1 is also identified graphically since the light blue area is not horizontal. Strict control of X2 is key to obtain tablets with good dissolution properties. For Stage 1, it is recommended to maintain X2 within 3.8 and 3.9 while X1 can vary within the whole domain explored, i.e. from 27.7 to 28.2.
When considering each time point separately, then the marginal predictive probabilities of success over the X1 and X2 experimental domain are show in Figure   5 . As it can be seen in Figure 5 , there is high likelihood to pass specifications at 2 hours, whatever the X1 and X2 levels. However the risk of failure at 8 hours and 14 hours depends heavily on the level of X2, The requirement to control X2 within 3.8 and 3.9
is essential due to these two time points in the form of a compromise.
The In the case presented, a non-informative prior was used, so that the mean of the posteriors was nearly equal to the maximum likelihood estimates of the parameters.
The main difference was the fact that the joint distribution of the parameters was available to derive numerically the predictive distribution of future responses, whatever the transformations (and the back-transformations) performed.
Such computation can easily be implemented using common statistical languages such as R or SAS, and with MCMC sampler such as MCMChregress, Winbugs or STAN.
